|A/Prof. Christoph Hagemeyer|
With a focus on individualised precision medicine to treat a range of human diseases, the researchers have backgrounds in physics, chemistry, biomedical imaging, advanced nano-bio-technologies, and immunotherapy.
State-of-the-art patient scanning techniques using technologies such as a simultaneous magnetic resonance imaging and positron emission tomography (MR-PET) scanner will be integrated with leading biomedical imaging research, equipment design and clinical work.
"We are excited to be part of this international Network of Excellence for Molecular Imaging and Precision Radiopharmaceuticals, " says Associate Professor Hagemeyer. "Targeted radiotherapy and molecular diagnostics are one of the fastest growing fields of translational medicine at the moment and together with our world-class overseas partners in Germany and Canada, Monash will play a leading role in this area in the future.We have visited HZDR in Dresden in March this year to grow our scientific exchange program and with the recent funding support we will accelerate our work towards large national and international grant applications. Within the new program, our groups at ACBD will work on novel recombinant antibodies for radio tracer delivery, site-specific bio conjugation and preclinical PET CT imaging."
To find out more on the collaboration and it's connection to the Australian Precision Radiopharmaceuticals Facility in the Monash University Innovation Precinct, click on the Monash Biomedical Imaging article here.